Advertisement

Topics

Companies Related to "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" [Most Relevant Company Matches] - Page: 2 RSS

05:37 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" found in our extensive corporate database of over 50,000 company records.

Showing "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" Companies 26–50 of 1,900+

Relevant

ALX Oncology

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobuli...


Corixa Corporation

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune disease, cancer and infectious disease by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis...

Alexo Therapeutics

Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin....


Cold Genesys Inc.

Cold Genesys, Inc. is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. In 2010, Cold Genesys acquired exclusive worldwide rights to develop CG0070 from BioSante Pharmaceuticals. CG0070 is currently under investigation in a Phase II, single-arm, open-label, pivotal study (BOND II) for patient...

Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in tri...

Immune-Onc Therapeutics, Inc.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer pat...

Genetic Immunity

US/Hungarian Genetic Immunity and US/Italian ViroStatics, both spin-offs of the non-profit Research Institute for Human and Genetic Therapy (RIGHT), are developing novel treatments for HIV/AIDS and other chronic diseases. The two companies are in the process of merging to form Immunacia – a multinational biopharmaceutical company with Business, Medica...

Biotec Pharmacon

Biotec Pharmacon develops, manufactures, and markets immune modulating compounds and molecular biology grade enzymes, based on own research in immunology and marine biotechnology

NAM Asia Hong Kong Co., Ltd.

CEO Teppei Nakano graduated from Keio University School of Medicine in 2017. We have been adopting IPA unexplored projects by the Ministry of Economy, Trade and Industry, which represent a large number of representatives of IT companies representing Japan, twice in 2016 and 2017, independent businesses that have been adopted by unexplored This is the NAM p...

Plantiva

Founded in 1993, Plantiva is the result of years of dedication by doctors and scientists in numerous fields of healthcare, including TCM pharmacognosy, Western medicine, Oriental medicine, molecular biology, and analytical chemistry, who are dedicated to providing only the highest quality botanical health products. Plantiva's unsurpassed commitment to quality has helped produce botanical formulas ...

S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug ...

Gritstone Oncology, Inc.

Gritstone is a privately-held company developing personalized cancer immunotherapies to fight multiple cancer types. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors and deep financial backing to tackle fundamental challenges at the intersection of cancer g...

Amazon Biotech

Amazon Biotech (OTCBB: AMZB) was established in 2003 to focus on the research and development of novel all-natural drugs for a better quality of life, by using the best of traditional medicines from the Amazon and Mother Nature. Amazon Biotech goal is to be a world leader and contributor in the treatment of HIV naturally through the use of Immune-based therapies (IBT). An Immune-Based Therapy i...

Immune Biosolutions Inc.

Immune Biosolutions (IBio) is an innovative biotech company specialized in the discovery and engineering of chicken humanized antibodies that target proteins with a recognized, yet unexploited, therapeutic potential. Through its Nebula Antibody Platform, Immune Biosolutions generates high-value recombinant antibody portfolios against historically difficult...

ConsortiaTX, Inc.

ConsortiaTX, Inc. is a biotherapeutic company developing therapies based on microbes and microbial products to prevent and treat human diseases. The company was formed in June of 2017 based on the research of Lynn Bry, M.D., Ph.D., Talal Chatila, M.D., and Georg Gerber M.D., Ph.D. The company’s initial therapeutic candidate, CTX-944, tar...

XDx Inc

Founded in 2000, XDx is a molecular diagnostics company based in South San Francisco, Calif. Setting the stage for a new era in personalized medicine, XDx is one of the first companies to develop and commercialize practical applications built on insights from the Human Genome Project. The company has developed a proprietary new method for noninvasively monitoring the immune system by measuring gen...

Acerta Pharma B.V.

Acerta is a leader in the field of covalent binding technology and is applying this technology to create novel selective therapies intended for the treatment of cancer and autoimmune diseases. Acerta’s lead molecule, acalabrutinib (ACP-196), is a selective and potent inhibitor of Btk. Acerta is also developing ACP-319, a novel selective inhibitor of P...

Biotec Pharmacon ASA

Biotec Pharmacon develops, manufactures, and markets immune modulating compounds and molecular biology grade enzymes, based on own research in immunology and marine biotechnology.

Akari Therapeutics Plc

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5 and Leukotriene B4 (LTB4), including paroxysmal nocturnal hemoglobinuria (“PNH”), atypical Hemolytic Uremic ...

IRX Therapeutics, Inc.

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine co...

Agenus, Inc.

Agenus is an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte Display® is used to generate fully human therapeutic antibody drug c...

XDx, Inc.

Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary new method for noninvasively monitoring immune system activity by measuring g...

MabSpace Biosciences Co., Limited

MabSpace Biosciences Co., Ltd. is a private, venture-backed biotechnology company specialized in discovering and developing innovative antibody therapeutics using its proprietary immune tolerance breaking technology platform. MabSpace has built up a pipeline in immune-oncology, ophthalmology as well as nephrology. The immune-oncology (IO) pipeline is spear...

AndroScience Corporation

Founded in 2000, AndroScience Corporation (ASC) is developing two novel small molecule platforms based on the therapeutic targets of the androgen receptor (AR) and select members of the Signal Transducer and Activator of Transcription (STAT) signaling pathway. The first patented family of compounds function through the enhancing degradation of AR protein, a novel mechanism of action described as A...

ImmuNext, Inc.

ImmuNext is developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. We are targeting critical immuno-regulatory molecules that either promote or suppress immune responses to restore immune homeostasis and cure disease. Using antibody-based therapeutics and novel recombinant fusion proteins, we are developing a...


More From BioPortfolio on "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks